Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

161. Systematic review of prevalence, treatments and clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and uncommon EGFR mutations

Systematic review of prevalence, treatments and clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and uncommon EGFR mutations Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

162. The value of Lunx-mRNA positive expression and clinicopathology in non-small cell lung cancer: a meta-analysis

The value of Lunx-mRNA positive expression and clinicopathology in non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

163. Ethnic differences in the prevalence of pulmonary nodules and the probability of malignancy on baseline CT screening for lung cancer: a meta-analysis

Ethnic differences in the prevalence of pulmonary nodules and the probability of malignancy on baseline CT screening for lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

164. Gender differences in benefits of lung cancer screening

Gender differences in benefits of lung cancer screening Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

165. Effects of physical training in health outcomes in old adults with lung cancer

Effects of physical training in health outcomes in old adults with lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

166. The efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive gene mutation ( EGFR (+) and KRAS (+) : a meta-analysis of randomized controlled trials

The efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive gene mutation ( EGFR (+) and KRAS (+) : a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

167. The stair-climbing test for the preoperative evaluation of lung cancer surgery candidates: a meta-analysis

The stair-climbing test for the preoperative evaluation of lung cancer surgery candidates: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

168. Prevalence of chronic co-existing illness in a lung cancer screening population: a systematic review and meta-analysis

Prevalence of chronic co-existing illness in a lung cancer screening population: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

169. Optimal starting age for lung cancer screening with low-dose computed tomography: a population level analysis

Optimal starting age for lung cancer screening with low-dose computed tomography: a population level analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

170. Impact of immune therapy in elderly patients with non-small cell lung cancer

Impact of immune therapy in elderly patients with non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

171. Determinants of patient experiences during the lung cancer pathway: a systematic review

Determinants of patient experiences during the lung cancer pathway: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

172. Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid small-sized non-small cell lung cancer

Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid small-sized non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

173. Lobectomy compared to sublobar lung resection in synchronous non-small cell lung cancer

Lobectomy compared to sublobar lung resection in synchronous non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

174. Evaluating interventions for meningeal metastasis originating from lung cancer: a systematic review and network meta-analysis

Evaluating interventions for meningeal metastasis originating from lung cancer: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

175. Sex and gender difference in risk of developing lung cancer and lung cancer specific survival: a systematic review and meta-analysis

Sex and gender difference in risk of developing lung cancer and lung cancer specific survival: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

176. Prognostic value of pre-treatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis

Prognostic value of pre-treatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

177. Residential radon and lung cancer risk by histologic subtype: a meta-analysis of case-control studies

Residential radon and lung cancer risk by histologic subtype: a meta-analysis of case-control studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

178. Relationship between microRNA expressions and the importance on its chemoresistance and susceptibility in lung cancer: a systematic review and meta-analysis protocol

Relationship between microRNA expressions and the importance on its chemoresistance and susceptibility in lung cancer: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

179. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Full Text available with Trip Pro

Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and stem cell factor receptor (c-Kit). In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced (...) non-small cell lung cancer patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial.Patients were randomized (2:1) to anlotinib or placebo up to progression or intolerable toxicity. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and managed by investigators. Key

2019 Thoracic cancer Controlled trial quality: uncertain

180. Performance of the Brock model for predicting lung cancer: a systematic review and meta-analysis

Performance of the Brock model for predicting lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO